lansoprazole has been researched along with sch 28080 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagaya, H; Satoh, H | 1 |
| Onur, R; Yenisehirli, A | 2 |
| Hibino, T; Ishii, Y; Levin, M; Nishino, A | 1 |
| Arikawa, Y; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
5 other study(ies) available for lansoprazole and sch 28080
| Article | Year |
|---|---|
[Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Binding Sites; Binding, Competitive; Biotransformation; Disulfides; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Imidazoles; Lansoprazole; Omeprazole; Potassium | 1992 |
Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Heart Atria; Imidazoles; In Vitro Techniques; Lansoprazole; Male; Milrinone; Myocardial Contraction; Omeprazole; Ouabain; Phosphodiesterase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Theophylline; Verapamil | 2005 |
Ion flow regulates left-right asymmetry in sea urchin development.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Body Patterning; Calcimycin; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Embryonic Development; Enzyme Inhibitors; Gene Expression Regulation, Developmental; Imidazoles; Ionophores; Ions; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Sea Urchins | 2006 |
Specific H+/K(+)-ATPase inhibitors decreased contractile responses of isolated rat vas deferens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adrenergic alpha-Agonists; Animals; Calcium; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Imidazoles; In Vitro Techniques; Lansoprazole; Male; Muscle Contraction; Muscle, Smooth; Omeprazole; Ouabain; Phenylephrine; Potassium; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Vas Deferens | 2006 |
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Dithiothreitol; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Imidazoles; In Vitro Techniques; Kinetics; Lansoprazole; Ligation; Male; Potassium; Proton Pump Inhibitors; Pylorus; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach; Sulfonamides; Swine | 2010 |